Confronting TB/HIV in the era of increasing anti-TB drug resistance

Journal of the International AIDS Society

Volumn 11, Issue 1, 2008, Pages 6-

  Chakaya, Jeremiah ^a   Getahun, Haileyesus ^b   Granich, Reuben ^b   Havlir, Diane ^c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951806986     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-11-6     Document Type: Review

References (35)

1. Global Tuberculosis Control: Surveillance, planning and financing. WHO Report 2008. WHO/HTM/TB/2008.293
2. UNAIDS: AIDS epidemic update: December 2007. UNAIDS/07.27E/JC1322.
3. Chaisson Richard E, Martinson Neil: Tuberculsosis in Africa – Combating an HIV driven crisis. NEJM 2008, 358(11):1089-1092.
4. De Cock KM, Chairsson RE: Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999, 3:457-465.
5. Harries AD: Tuberculosis and human immunodeficiency infection in developing countries. Lancet 1990, 335:387-390.
6. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. The antiretroviral therapy collaboration. Arch Intern Med 2005, 165:416-423.
7. Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D, on behalf of the Clinical Epidemiology Group of the French Hospital Database on HIV: Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008, 9(4):246-256.
8. World Health Organization: Interim policy on collaborative TB-HIV activities. Geneva, Switzerland: WHO; 2004. WHO/HTM/TB/2004.330;WHO/HTM/HIV2004.1
9. Corneli A, Jarrett NM, Sabue M, et al.: Patient and provider perspectives on implementation models of HIV counseling and testing for patients with TB. Int J Tuberc Lung Dis 2008, 12(3 Suppl 1):79-84.
10. Chakaya JM, Mansoer JR, Scano F, et al.: National scale-up of HIV testing and provision of HIV care to tuberculosis patients in Kenya. Int J Tuberc Lung Dis 2008, 12(4):424-9.
11. Smieja MJ, Marchetti CA, Cook DJ, Small FM: Isoniazid for preventing tuberculosis in non-HIV infected persons(Review). Cochrane Database of Systematic Reviews 1999:CD 001363. DOI: 10.1002/14651858.CD 001363
12. Woldehanna S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons(Review). Cochrane Database of Systematic Reviews 2004:CD 000171. DOI:10. 1002/14651858.CD000172.pub2
13. Zar Heather J, Cotton Mark F, Strauss Stanzi, et al.: Effect of Isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial. BMJ 2007, 334:136.
14. Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA: Preventive chemotherapy for HIV associated tuberculosis in Uganda: an operational assessment at a voluntary counseling and testing centre. AIDS 1995, 9(3):263-73.
15. Mugisha B, Bock N, Mermin J, Odeke RM, Miller B, Adatu-Engwau F, Granich R, Bunnell R: Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing centre in Uganda. Int J Tuberc Lung Dis 2006, 10(7):761-767.
16. Girardi Enrico, Sabin Caroline A, Montarte Antonell d' Amino, et al.: Incidence of tuberculosis among HIV infected patients receiving highly active antiretroviral therapy in Europe and North America. Clinical Infectious Diseases 2005, 41:1772-82.
17. Badri M, Wilson D, Wood R: Effect of highly active anti-retroviral therapy on the incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359(9323):2059-2064.
18. Golub Jonathan E, Saracen Valeria, Covalcante Solange C, et al.: The impact of antiretroviral therapy and Isoniazid preventive therapy on tuberculosis incidence in HIV infected patients in Rio de Janeiro, Brazil. AIDS 2007, 21:1441-144.
19. Havlir Diane V, Getahun Haileyesus, Sanne Ian, et al.: Oppurtunities and challenges in overlapping HIV and TB epidemics. JAMA 2008, 300(4):423-430.
20. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD: Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006, 12(5):744-51.
21. Cohen T, Lipsitch M, Walensky RP, Murray M: Beneficial and perverse effects of Isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis co-infected populations. Proc Natl Acad Sci USA 2006, 103(18):7042-7.
22. Lawn Stephen D, Landon Myer, Linda-Gail Bekker, Wood Robin: Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006, 20:1605-1612.
23. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. WHO, Geneva; 1999. WHO/CDS/TB/99.269
24. Tuberculosis infection control in the era of expanding HIV care and treatment – Addendum to WHO Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. World Health Organization, Geneva; 2007. WHO/HTM/TB/99.269
25. Zachariah R, Fitzgerald M, Massaquoi M, et al.: Does antiretroviral treatment reduce case fatality among HIV positive patients with tuberculosis in Malawi. Int J Tuberc Lung Dis 2007, 11:848-853.
26. Lawn Stephen D, Myer Landon, Bekker Linda-Gail, Wood Robin: Tuberculosis associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007, 21:335-341.
27. Ozick LA, Jacob L, Comer GM, et al.: Hepatotoxicity from Isoniazid and rifampicin in inner city AIDS patients. Am J Gastroentol 1995, 90:1978-1980.
28. Yimer Getnet, Aderaye Getachew, Amogne Wondwossen, et al.: Anti-Tuberculosis therapy induced hepatotoxicity among Ethiopian HIV positive and negative patients. PLoSONE 3(3):e1809. doi.10.1371/journal.pone.0001809
29. Padmapriyadarsini C, Chandrabase J, Victor L, Hanna LE, Arunkumar N, Swaminathan S: Hepatitis B or hepatitis C co-infection in individuals infected virus and effect of anti-tuberculous drugs on liver function. J Postgrad Med 2006, 52:92-6.
30. MMWR: 55:11.2006, March 24
31. Gandhi NR, Moll A, Sturm AW, et al.: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547): 1575-80. 2006 Nov 4
32. Wells Charles D, Peter Cegielski J, Nelson Lisa J, et al.: HIV Infection and Multi drug resistant tuberculosis – the perfect storm. Journal of Infectious Diseases 2007, 196:S86-107.
33. Dubrovina I, Miskinis K, Lyepshina S, et al.: Drug resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics. Int J Tuberc Lung Dis 2008, 12(7):758-762.
34. Anti-Tuberculosis Drug Resistance in the world Report No 4. The WHO/IUATLD Global project on anti-tuberculosis drug resistance surveillance. WHO/HTM/TB/2008.394
35. Koenig R: Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 319(5865):894-7. 2008 Feb 15